Showing 6431-6440 of 8236 results for "".
- FDA Nod for Cyltezo Autoinjector Penhttps://practicaldermatology.com/news/fda-nod-for-cyltezo-autoinjector-pen/2461738/The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). Cyltezo is an FDA-approved interchangeable biosimilar to Humira (adalimumab). Initially approved as a pre
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encour
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr
- Participating in an AD Trial: Weighing What Matters Most to Patients and Parentshttps://practicaldermatology.com/news/participating-in-an-ad-trial-weighing-what-matters-most-to-patients-and-parents/2461714/Key differences exist between what adults with eczema value for themselves in clinical trial participation versus what parents find important for their kids with this chronic skin disease, according to new research from the
- Mindfulness and Self-compassion Training Improve QOL for AD Patientshttps://practicaldermatology.com/news/mindfulness-and-self-compassion-training-improve-qol-for-ad-patients/2461713/Online group mindfulness and self-compassion training improves quality of life in adults with atopic dermatitis (AD). In this randomized clinical trial of 107 adults with AD, mindfulness and self-compassion training in addition to usual care showed significantly greater improvement
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang